

EXPRESSION AND PURIFICATION OF AN HTLV-III GAG/ENV GENE PROTEIN

5 The present invention relates to a protein designated
gag/env, which comprises the core protein (gag) and the
envelope protein (env) of the HTLV-III virus, the etiologic
agent for acquired immune deficiency syndrome (AIDS). This
protein is produced through organic synthetic methods or
10 through the use of recombinant DNA techniques in which the
requisite gene sequences are inserted by means of a suitable
DNA vector into a compatible unicellular host organism.

 This invention further relates to the isolation and
15 purification of the gag/env protein and to methods for the
detection of AIDS antibodies or viruses in human sera or
other biological fluids and for the immunoprophylactic
protection of human beings against AIDS, based on the use of
the protein.

20

 In 1985 nearly 8,000 people were diagnosed as having
AIDS, and the number has been steadily increasing. Fifteen
thousand more cases are expected to be diagnosed in 1986,
and the number of cases may well double again in 1987 [New
25 York Times Magazine, March 2, 1986, p. 42]. AIDS has been
characterized by the onset of severe opportunistic infec-
tions secondary to an effect on the body's immune system
[Gottlieb et al., New Eng. J. Med. 305:1425 (1981)]. The
disease has been found in male homosexuals, patients
30 receiving blood products, intravenous drug addicts and
individuals originating from Haiti and Central Africa [Piot
et al., Lancet 11:65 (1984)]:

 The causative agent was suspected to be of viral origin
35 because the epidemiological pattern of AIDS was consistent

with that of a transmissible disease. At least three retro-
viruses have been isolated from cultured T-cells of several
patients with AIDS, or from white blood cells of persons at
risk for the disease. A novel human retrovirus called
5 lymphadenopathy-associated virus (LAV) was discovered, and
its properties were consistent with an etiological role in
AIDS. That virus was isolated from a patient with lymphadenopathy and hence the name [Montagnier et al., in Human
T-Cell Leukemia/Lymphoma Virus, R.C. Gallo et al. eds., Cold
10 Spring Harbor Laboratory, pp. 363-370 (1984)].

Other human retroviruses, specifically two subgroups of
the human T-cell leukemia/lymphoma/lymphotropic virus, types
I [Poiesz et al., Proc. Natl. Acad. Sci. U.S.A. 77:7415
15 (1980)] and III [Popovic et al., Science 224:497 (1984)]
have also been isolated. Still another virus, called the
AIDS-associated retrovirus (ARV), has been proposed as the
causative agent [Levy et al., Science 225:840 (1984)]. Both
the HTLV-III and ARV retroviruses display biological and
20 seroepidemiological properties similar to LAV [Levy et al.,
supra, Popovic et al., supra]. Thus, at least three retro-
viruses have been postulated to be the etiologic agent or
AIDS: LAV, ARV, and HTLV-III. For this application, these
viruses will be collectively referred to as the AIDS
25 viruses. Because HTLV-III is the prototypic virus for this
group, it will be understood that the term "antigenic deter-
minant corresponding to the sequences of a protein of an
HTLV-III virus" actually refers to the sequences of the
proteins of any of the AIDS viruses.

30

One reason for the difficulty in determining the true
etiologic agent of AIDS was cross-reactivity of various
retroviral antigens with serum samples from AIDS patients.
For example, serum samples from AIDS patients have been
35 shown to react with antigens of both HTLV-I [Essex et al.,
Science 220:859 (1983)] and HTLV-III [Sarngadharan et al.,
Science 224:506 (1984)]. Envelope gene products of HTLV

demonstrated antigenicities that were cross-reactive with antibodies in sera from adult T-cell leukemia patients [Kiyokawa et al., Proc. Natl. Acad. Sci. U.S.A. 81:6202 (1984)]. Adult T-cell leukemias (ATL) differ from acquired
5 immune deficiency syndrome (AIDS) in that HTLV-I causes T-cell malignancies that are characterized by the uncontrolled growth of T-cells. In AIDS, instead of cell growth there is cell death. In fact this cytopathic characteristic of HTLV-III was critical to ultimately determining the
10 specific retroviral origin of the disease.

The etiologic agent of AIDS was isolated by the use of immortalized human neoplastic T cell lines (HT) infected with the cytopathic retrovirus characteristic of AIDS,
15 isolated from AIDS afflicted patients. Seroepidemiological assays using this virus showed a complete correlation between AIDS and the presence of antibodies to HTLV-III viral antigens [Montagnier et al., supra; Sarngadharan et al., supra; Schüpbach et al., Science 224:503 (1984)]. In
20 addition, nearly 85% of patients with lymphadenopathy syndrome and a significant proportion of asymptomatic homosexual men in AIDS endemic areas were also found to carry circulating antibodies to HTLV-III. Taken together, these data implicate HTLV-III as the principal etiologic
25 agent for AIDS.

Until the successful culturing of the AIDS virus using the H-9 cell line, the env AIDS protein of the AIDS virus had not been isolated, characterized or synthesized. This in
30 major part was due to the fact that the virus is cytopathic, and isolation of the virus was thus not possible [Popovic et al., supra]. Once a human T-cell line that was resistant to the cytopathic effects of the virus was discovered, however, the molecular cloning of AIDS proviral DNA could be carried
35 out.

The need for sensitive and rapid methods for the diagnosis of AIDS in human blood and in other biological fluids and for a method to prevent the disease by vaccination is very great. Virtually all of the assays and tests presently available are fraught with errors. In fact, the Center for Disease Control (CDC) has indicated that presently available tests should be used solely for screening units of blood for the presence of antibodies to HTLV-III. The CDC has even gone further by stating that the presently available enzyme-linked immunosorbent assay (ELISA) tests should not be used for the general screening of high risk populations or as a diagnostic test for AIDS [Federal Register 50(48):9909, March 12, 1985].

The errors in previously used AIDS tests have been traced to the failure to use a specific antigenic protein of the etiologic agent for AIDS. The previously used proteins were derived from a viral lysate. Since the lysate is made from human cells infected with the virus, i.e. the cells used to grow the virus, the lysate will contain human proteins as well as viral proteins. Thus preparation of a pure antigen of viral protein is very difficult. The antigens used until now have thus produced both false positive and false negative results [Budiansky, Nature 312: 583 (1984)]. The errors caused by the use of such lysate proteins/peptides could be avoided by using a composition for binding AIDS antibodies which is substantially free of the non-AIDS specific proteins. Compositions of substantially pure AIDS envelope and core protein can be used as antigens.

Both the envelope and core proteins of HTLV-III have conserved antigenic determinants which would permit their use to screen for, diagnose and/or provide protection by vaccination against the AIDS viruses. And individuals that have been exposed to HTLV-III and who may thus be at risk to contract AIDS or who have the disease can be identified by the presence in their blood of antibodies to the viral core

protein (gag) and/or the envelope protein (env),
[Sarngadharan et al., Science 224:506 (1984)].

5 The availability of a reliable and sensitive test for
the presence in blood or in other biological fluids of the
AIDS virus itself, or of particles therefrom, is also
important. Groopman et al. [Blood 66:742 (1985)] have
reported that antibodies against AIDS viruses are not always
present in the blood of AIDS victims. Groopman et al.
10 examined one patient with AIDS and another with related
disorders (ARC) from whom blood samples were taken which
were antibody negative but from which HTLV-III could be
cultured.

15 Recombinant DNA technology has recently been applied to
the AIDS problem. The molecular cloning and expression of
the env gene from HTLV-III has been reported [Crowl et al.,
Cell 41:979 (1985); Chang et al., Biotechnology 3:905
(1985)]. Dowbenko et al. [Proc. Natl. Acad. Sci. U.S.A.
20 82:7748 (1985)] have expressed the HTLV-III core protein in
E. coli.

Through the use of such genetic engineering techniques,
purified viral antigens that are safe, reliable and less
25 costly to produce have become available. Even more advan-
tageous, however, would be the availability of a viral
protein having antigenic determinants that are present on
both the env and the gag proteins. Such a protein would be
an exceptionally powerful tool for the detection of AIDS
30 antibodies, and it could serve as the basis for a variety of
sensitive diagnostic tests and for a possible vaccine
against the AIDS virus.

Therefore a novel protein, comprising 50 or more amino
35 acids, designated gag/env, and having an amino acid sequence
corresponding to at least one antigenic determinant of a
HTLV-III gag protein and of a HTLV-III env protein has been
provided which permits to

screen for, diagnose and/or protect by vaccination against the AIDS virus. The novel gag/env protein can be represented by the amino acid sequence shown in Figure 2 or a functional equivalent thereof.

5 The invention further provides the requisite DNA sequences coding for the gag/env polypeptide of the present invention, recombinant vectors containing such DNA sequences, and unicellular organisms useful in the production
10 through recombinant DNA technology of the gag/env protein of the present invention as well as processes for the manufacture of such DNA sequences, recombinant vectors and unicellular organisms. In addition methods are described for the expression and isolation of the gag/env protein of the
15 present invention. The gag/env protein thus produced may be utilized by the methods of this invention for a number of important immunological processes.

Through use as a diagnostic reagent, the gag/env protein
20 can be used to detect the presence of antibodies against AIDS viruses in human sera or in other biological fluids such as tears, semen, vaginal secretions and saliva. Because the protein can be prepared in a homogeneous form, problems of non-specific reactions which have plagued the use of
25 diagnostic reagents based upon relatively crude HTLV-III viral protein isolates in the past are eliminated.

Used as an immunogen, the gag/env protein can be employed to produce antibodies in animals against the
30 antigenic determinants contained therein. Such antibodies can in turn be used, in conjunction with the gag/env protein which has been suitably labeled, in a radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA) to detect the presence of HTLV-III viruses or particles therefrom in human
35 serum or in other biological fluids such as tears, semen, vaginal secretions and saliva. Particles (or fragments) that could be detected by these methods include of course pieces

of the viral core or envelope proteins.

By incorporation into a suitable vaccine formulation, the gag/env protein of the present invention may further be used to combat the spread of AIDS through prophylactic immunization.

There are important advantages to using the gag/env protein of the invention, compared to using separate gag and env proteins. The env protein itself is very insoluble, which makes purification difficult. Combination of the two proteins results in a product that is more easily solublized and therefore more easily purified. Large-scale production and purification are also simplified, of course, since only a single compound must be isolated. Finally, the gag/env protein makes possible the development of a diagnostic kit which works better in an antigen sandwich assay than would separate gag and env proteins.

Although the gag/env protein was derived from HTLV-III, it must be understood that the diagnostic and immunoprophylactic methods described herein are applicable to the detection of any of the other viral agents which have been implicated in or associated with AIDS such as lymphadenopathy-associated virus (LAV) and AIDS-associated retrovirus (ARV). This is because Crowl et al. [Cell 41: 979 (1985)] have shown that proteins from these viral agents are immunologically related to those of HTLV-III and have amino acid sequence segments in common.

The present invention may be more readily understood on the basis of the following detailed description when considered in connection with the following figures, wherein

FIG. 1 is a schematic representation of expression plasmids which directs the synthesis of gag (upper drawing) and gag/env (lower drawing) proteins. Restriction endo-

nuclease sites delineating the gag and env genes are shown, and the cross-hatched region denotes the env segment of the gag/env fusion gene. In both plasmids transcription is under the control of the λ P_L promoter, and translation initiation signals are from plasmid pEV-vrf2;

FIG. 2 shows the nucleic acid sequence of the gag/env fusion gene (with selected position numbers and restriction endonuclease sites indicated) and the amino acid sequence of the gag/env protein predicted therefrom; and

FIG. 3 shows the results of SDS-polyacrylamide gel electrophoretic analysis of the gag/env protein produced in *E. coli*. Panel 1 shows Coomassie*blue-stained total cell proteins from cells harboring the recombinant plasmid carrying the gag/env fusion gene and from control cells. Panels 2 and 3 are Western blots of total cell protein probed with either rabbit antibodies against env peptide 500-511 (panel 2) or sheep antibodies against gag p24 (panel 3). The immune complexes in panels 2 and 3 were visualized by a second antibody labeled with horseradish peroxidase. In all three panels g/e refers to the gag/env protein, and c refers to a negative control sample used to show specificity. The mobilities of molecular weight standards (in kD) are shown, and the position of the gag/env protein band in the gels is indicated by the arrows.

The methods of this invention entail a number of steps which, in logical sequence, include (1) identification and isolation of the genes encoding the gag and env proteins or fragments thereof, (2) insertion of these genes or gene fragments into an appropriate cloning vehicle to produce a recombinant vector containing a gag/env fusion gene, (3) transfer of the recombinant cloning vehicle into a compatible single cell host organism, (4) selection and growth of properly modified hosts that can replicate and express the inserted gene sequences, (5) identification and purification

* Registered Trade Mark

of the gene product, (6) use of the gene product to detect antibodies against HTLV-III or related viruses or as an immunogen to produce antibodies that can in turn be used to detect the viruses themselves or fragments therefrom in human sera or in other biological fluids, and (7) use of the gag/env protein in a vaccine formulation for possible immunoprophylactic protection against AIDS.

Isolated HTLV-III virions could be used as the source for both the gag and the env genes of the invention. For example, Dowbenko et al. [Proc. Natl. Acad. Sci. U.S.A. 82:7748 (1985)] have used a 2.2 kilobase (kb) fragment from the 5' region of the viral genome as a source of the gag gene. Alternatively, genomic DNA from cells into which the proviral genome of HTLV-III has been integrated can be the gene source [Shaw et al., Science 226:1165 (1984)]. Crowl et al. [Cell 41:979 (1985)] have used such genomic DNA from H9 cells infected with HTLV-III to obtain the env gene.

Alternatives to the isolation of the gag and env genes include but are not limited to the chemical synthesis of the gene sequences and the preparation of DNA that is complementary to the messenger RNA produced from the genes.

Regardless of its source, DNA encoding the gag and env proteins can be cloned into bacteria, and clones containing the gag or env genes can be identified by methods that are well known in the art. For example, complimentary DNA (cDNA) probes could be prepared for the genes and used to detect clones bearing the genes through hybridization techniques.

In a preferred embodiment of the present invention, a genomic library constructed by XbaI digestion of the DNA of the HTLV-III-infected H9 cells described above was cloned using a phage λ vector, and clones bearing the HTLV-III proviral genome were identified by hybridization with HTLV-III cDNA. One such clone was designated λ HXB-3, and a

1700 base-pair fragment encoding most of the gag precursor protein was isolated by ClaI/HincII digestion of the DNA from this clone.

- 5 The immediate source of env gene sequences used in the preferred embodiment of the invention was a derivative of plasmid pEV3/env 44-640 that had env codons corresponding to residues 514-524 deleted. This deletion surprisingly results in a significant increase in the expression of the env gene.
- 10 Env sequences containing codons 467 to 640 were obtained by the BglIII/HindIII cleavage of plasmid pEV3/env 44-640.

Once identified and isolated, the gag and env genes of HTLV-III are inserted into an appropriate expression vehicle

15 which contains the elements necessary for transcription and translation of the inserted gene sequences. Useful cloning vehicles may consist of segments of chromosomal, nonchromosomal and synthetic DNA sequences such as various known bacterial plasmids, phage DNA, combinations of plasmids and

20 phage DNAs such as plasmids which have been modified to employ phage DNA or other expression control sequences, or yeast plasmids. Specific cloning vehicles which could be used include but are not limited to the pEV-vrf plasmids (pEV-vrf1, -2 and -3), SV40, adenovirus, yeast, lambda

25 gt-WES-lambda B, Charon 4A and 28, lambda-gt-1-lambda B, M13-derived vectors such as pUC8, 9, 18 and 19, pBR313, 322 and 325, pAC105, pVA51, pACY177, pKH47, pACYC184, pUB110, pMB9, ColE1, pSC101, pml21, RSF2124, pCR1 or RP4.

- 30 The insertion of the gag and env genes into a cloning vector is easily accomplished when both the genes and the desired cloning vehicle have been cut with the same restriction enzyme or enzymes, since complementary DNA termini are thereby produced. If this cannot be accomplished, it may be
- 35 necessary to modify the cut ends that are produced by digesting back single-stranded DNA to produce blunt ends, or by achieving the same result by filling in the single-

-stranded termini with an appropriate DNA polymerase. In this way, blunt-end ligation with an enzyme such as T4 DNA ligase may be carried out. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini. Such linkers may comprise specific oligonucleotide sequences that encode restriction site recognition sequences. The cleaved vector and the gag and env gene fragments may also be modified by homopolymeric tailing, as described by Morrow [Methods in Enzymology 68:3 (1979)].

Once either the gag or env gene or a fragment thereof has been inserted into an appropriate cloning vehicle, the other gene or gene fragment can be introduced into the vehicle by judicious restriction endonuclease cleavage to place the second gene or gene fragment into juxtaposition with the first, thereby creating a fusion gene. Of course if the gag and env genes are chemically synthesized, the fusion gene could be directly produced and introduced as a single DNA fragment into the cloning vehicle.

In the preferred embodiment of the present invention, the ClaI/HincII digestion fragment containing the gag gene from λ HXB-3 described above was ligated into plasmid pEV-vrf2 which had been cleaved with ClaI and PuvII to produce a recombinant expression plasmid pEV2/gag 15-512 (Fig. 1, upper drawing) that directed the synthesis of a 56 Kd protein comprising gag residues 15-512. The gag sequences downstream of a BglII site near residue 437 were then replaced with env sequences in a BglII/HindIII fragment from the derivative of plasmid pEV3/env 44-640 (having residues 514-524 deleted) described above to produce plasmid pEV2/gag 15-436/env 467-640 Δ 514-524 bearing the gag/env fusion gene (Fig. 1, lower drawing).

Full details of this construction are provided below in the section entitled "Example", in particular in subsections

B to E. The nucleic acid sequence of the gag/env gene of the preferred embodiment [determined by the chemical cleavage method of Maxam et al., Methods in Enzymology 65:499 (1980)] and the amino acid sequence of the gag/env protein predicted therefrom are shown in Fig. 2.

Many of the cloning vehicles that may be used in this invention contain one or more marker activities that may be used to select for desired transformants, such as ampicillin and tetracycline resistance in pBR322, ampicillin resistance and β -galactosidase activity in pUC8, and ampicillin resistance in pEV-vrf2. Selection of host cells into which such vectors have been inserted is greatly simplified when the host cells otherwise lack the activities contributed by the vectors.

It should be understood that the nucleotide sequences of the gag and env gene fragments inserted at a selected site in a cloning vehicle may include nucleotides which are not part of the actual structural genes. Alternatively, the gene fragments may contain only part of the complete genes. All that is required is that the gene fragments inserted into the cloning vehicle be capable of directing the production in an appropriate host organism of a polypeptide or protein having at least one antigenic determinant corresponding to the sequences of the gag and env proteins.

The selection of an appropriate host organism is affected by a number of factors known in the art. These factors include, for example, compatibility with the chosen vector, toxicity of proteins encoded by the hybrid plasmid, ease of recovery of the desired protein, expression characteristics, biosafety and costs. A balance of these factors must be struck, and it must be understood that not all hosts will be equally effective for expression of a particular recombinant DNA molecule.

Suitable host unicellular organisms which can be used in this invention include but are not limited to plant, mammalian or yeast cells and bacteria such as *Escherichia coli*, *Bacillus subtilis*, *Bacillus stearothermophilus* and Actinomyces. *Escherichia coli* strain MC1061, which has been described by Casadaban et al. [*J. Mol. Biol.* 138:179 (1980)], can be used as can be used any other strain of *E. coli* K-12 containing the plasmid pRK248cIts. Plasmid pRK248cIts for use in other *E. coli* K-12 strains is freely available from the American Type Culture Collection (ATCC) and has accession No. ATCC 33766. *E. coli* strain MC1061 has also been deposited at ATCC (accession No. ATCC 53338) and is also freely available upon request.

Transfer of the recombinant cloning vector into the host cell may be carried out in a variety of ways. Depending upon the particular vector/host cell system chosen, such transfer may be effected by transformation, transduction or transfection. Once such a modified host cell is produced, the cell can be cultured and the protein expression product may be isolated from the culture.

As produced in *E. coli*, the gag/env protein is largely confined to cytoplasmic inclusion bodies (insoluble protein aggregates) of the bacterium, a fact which greatly facilitates purification of the protein. To isolate the gag/env protein product of this invention, the bacterial cells are preferably disrupted or lysed and the insoluble protein is recovered by centrifugation. Substantial purification can then be obtained by sequential washing of the precipitate with increasing concentrations of urea followed by the use of standard protein purification techniques.

For small amounts of material such as samples taken for polyacrylamide gel electrophoretic analysis, the cells can be disrupted by treatment with a detergent such as sodium dodecyl sulfate (SDS). Larger quantities of the protein are

best recovered by sonication, or by other mechanically disruptive means, such as the French pressure cell.

Cell disruption could also be accomplished by chemical or enzymatic means. Since divalent cations are often required for cell membrane integrity, treatment with appropriate chelating agents such as EDTA or EGTA might prove sufficiently disruptive to facilitate the leakage of the protein from the cells. Similarly, enzymes such as lysozyme have been used to achieve the same result. That enzyme hydrolyzes the peptidoglycan backbone of the cell wall. The application of alternating freezing and thawing in conjunction with lysozyme treatment could also be employed.

Once freed from the cells, the gag/env protein may be identified in the mixture by any of the methods known in the art. For example, a radioimmunoassay or enzyme-linked immunosorbent assay could be carried out using antibodies against the protein. Preferably, the protein is identified by SDS polyacrylamide gel electrophoresis followed by Western blot or similar analysis.

The gag/env protein of the invention can be concentrated by precipitation with salts such as sodium or ammonium sulfate, by ultrafiltration or by the use of other methods well known to those skilled in the art. Further purification can be accomplished by conventional protein purification techniques including but not limited to gel filtration, ion-exchange chromatography, preparative disc-gel or curtain electrophoresis, isoelectric focusing, low temperature organic solvent fractionation or countercurrent distribution.

Because the gag/env protein contains antigenic determinants from two major components of the HTLV-III virus, and because this virus is the principal etiologic agent in AIDS and is immunologically related to the other viral agents which have been implicated in or associated with AIDS or

ARC, the protein is a powerful diagnostic tool for the detection of antibodies against AIDS viruses in human serum. The fusion can be used for this purpose in numerous ways known in the art.

5

For example, the gag/env protein could be labeled in any number of ways, the labeled protein could be added to a human serum sample suspected to contain antibodies against AIDS viruses to form labeled fusion protein-antibody
10 complexes, and the complexes thus formed could be detected by appropriate means. By way of further example, the protein could be immobilized on a solid support and then contacted with a human serum sample. Antibodies against AIDS viruses in the sample would bind to the immobilized protein, and the
15 complexes thus formed could be detected by the use of a reagent such as Staphylococcus aureus protein A (labeled, e.g., with Iodine-125) or a second anti-human IgG antibody (labeled, e.g., with a radioisotope or with horseradish or lactoperoxidase) after uncomplexed proteins and antibodies
20 have been washed away. Many variations on these themes will be apparent to the skilled artisan, some of which are suggested below.

Through the use of antibodies against the gag/env
25 protein, a variety of diagnostic tests for the presence of AIDS viruses or particles therefrom in human serum or in other biological fluids can be devised. Such antibodies can be produced by injecting a mammalian or avian animal with a sufficient amount of a vaccine formulation comprising the
30 protein and a compatible pharmaceutical carrier to elicit the production of antibodies against the protein. The appropriate amount of the protein which would be required would be known to one of skill in the art or could be determined by routine experimentation. As used in connection
35 with this invention, the term "pharmaceutical carrier" can mean either the standard compositions which are suitable for human administration or the typical adjuvants employed in

animal vaccinations.

Suitable adjuvants for the vaccination of animals include but are not limited to Freund's complete or incomplete adjuvant (not suitable for human or livestock use), Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostearate), and mineral gels such as aluminum hydroxide, aluminum phosphate and alum; surfactants such as hexadecylamine, octadecylamine, lysolecithin, dimethyldioctadecylammonium bromide, N_1 -N-dioctadecyl-N'-N-bis(2-hydroxyethyl-propanediamine), methoxyhexadecylglycerol, and pluronic polyols; polyanions such as pyran, dextran sulfate, poly IC, polyacrylic acid, carbopol^{*}; peptides such as muramyl dipeptide, dimethylglycine, tuftsin; and oil emulsions. The gag/env protein could also be administered following incorporation into liposomes or other microcarriers, or after conjugation to polysaccharides, other proteins or other polymers.

Typically, the initial vaccination is followed some weeks later by one or more "booster" vaccinations, the net effect of which is the production of high titers of antibodies against the gag/env protein, which can be harvested in the usual way.

Of course, monoclonal antibodies against the protein could be produced through current technology to achieve the same result. Somatic cells with the ability to produce antibodies, such as B cells, may be fused with myeloma cell lines to produce hybridoma cells. These cells may be cultured in vitro or as ascites tumors indefinitely to produce large quantities of specific antibodies. Because hybridoma cells may be readily cloned, it is possible to rapidly produce large numbers of cells, all of which produce the same specific antibody molecules directed to a common antigenic determinant. This exceptional uniformity in antibody production may be advantageous where the antibodies

* Registered Trade Mark

are to be used in specific diagnostic tests.

Lymph nodes and spleens of animals of animals primed by injection of an antigen are convenient sources of B cells, although it is equally feasible to remove these cells from unsensitized animals, and to prime them in vitro after isolation. Mouse and rat B lymphocytes are most frequently used in hybridoma production, but cells from rabbits, human beings, frogs or other animals might be used instead.

10

Numerous specialized myeloma cell lines have been developed from lymphocytic tumors for use in hybridoma production [Köhler and Milstein, European J. Immunol. 6:511 (1976); Shulman et al., Nature 276:269 (1978)]. Of the many such cell lines produced, P3/X63-Ag 8, P3/NSI/1-Ag 4-1, Sp2/O-Ag14, and S194/5.XX0.BU.1 have frequently been used.

15

The fusion of the antibody-producing spleen or lymph node cells with myeloma cells to produce hybridomas is usually carried out with an excess of splenocytes or lymphocytes over myeloma cells that may be as high as 20:1 although, typically, lower ratios are used. Fusion is facilitated by the use of a fusion-promoting agent such as UV-inactivated Sendai virus or polyethylene glycol (PEG). Gefter et al. [Somatic Cell Genet. 3:231 (1977)] have reported that combining dimethyl sulfoxide with PEG further enhances cell fusion. Electrical devices are also available which can fuse cells with an exceptionally high degree of efficiency.

25

30

Once fusion has occurred, the hybridoma cells must be selected from the unfused parental cell strains. This selection process may be readily accomplished by culturing the cells in a medium that supports hybridoma but not parental cell growth. The somatic B cells used in the fusion have limited lifespans in culture and thus will be lost as they undergo senescence and death, but the parental myeloma

35

cells, with indefinite culture lifespans, must be eliminated by special selection techniques.

In a commonly used system, myeloma cells lacking hypoxanthine phosphoribosyl transferase (HPRT⁻) are used. These cells lack the scavenger pathway for the reutilization of hypoxanthine free base and cannot survive if an inhibitor, such as aminopterin, is used to block the de novo purine synthetic pathways. The myeloma parental cells may thus be selected against by culturing the fusion mixture in hypoxanthine/aminopterin/thymidine (HAT) medium, while the hybridoma cells will survive due to the contribution of HPRT by the antibody-producing fusion parental cells.

After a period of selection culturing, the surviving hybridoma cells may be cloned, stocks may be grown up by standard cell culture methods, and clones producing desired specific immunoglobulins may be detected by enzyme-linked immunosorbent assay (ELISA) or by other tests, based upon the use of the antigen against which the antibodies are directed.

The anti-gag/env protein antibodies obtainable through the use of this invention may further be used for the preparation of a variety of diagnostic tests for AIDS viruses or particles therefrom. Such diagnostic systems could take the form of a radioimmunoassay, either in free solution or solid state. Alternatively, enzyme-linked immunosorbent assays could be produced, as could assays based on immunoblot analysis. These assays could be direct or indirect, with the application of a second antibody directed against the anti-gag/env protein antibodies. Numerous enzymatic activities could be coupled to the antibodies, with peroxidase, glucose oxidase, β -galactosidase and alkaline phosphatase being only a few of the possibilities.

The basic principle underlying many of these tests is that a human serum or other biological fluid sample suspected to contain AIDS viruses or fragments therefrom is reacted with a known titer of antibodies against the gag/env protein to form antigen-antibody complexes. The complexes thus formed are detected by an appropriate means.

Those skilled in the art will also recognize that there are many other ways in which anti-gag/env protein antiserum could be utilized in a diagnostic capacity, such as in one of a number of agglutination tests. In such agglutination assays, the interaction of antibodies and AIDS viruses or viral fragments may be detected using systems in which particles are coated with the anti-gag/env protein antibodies. Such particles may be latex beads, liposomes, erythrocytes, polyacrylamide beads, or any of a number of suitable polymers.

The method for the determination of AIDS virus or of antibodies against AIDS virus as described above can be conducted in suitable test kits comprising in a container the gag/env protein of the present invention or antibodies against AIDS virus elicited by the gag/env protein of the present invention.

Crowl et al. [Cell 41, 979-986 (1985)] have described that the serum of all of 50 AIDS patients tested with genetically engineered env protein was highly reactive to the protein. This was true despite the fact that half of these patients were from the west coast of the United States, and half were from the east coast. The fact that all of the sera tested were reactive to the env protein showed that the viruses producing the antibodies that thus reacted, although geographically separated and undoubtedly somewhat genetically different, must have had at least one common or conserved antigenic determinant in their envelope proteins.

The gag core protein of the AIDS retrovirus has been found to induce antibody formation in a large percentage of individuals who had previously been exposed to the virus [Montagnier et al., supra; Schüpbach et al., supra; 5 Sarngadharan et al., supra].

Taken together, the above observations suggest that the gag/env protein of this invention, which has at least one antigenic determinant corresponding to the sequences of the 10 gag and env proteins of which it is comprised, would be immunogenic in human beings and may be useful as an AIDS vaccine.

Thus, the gag/env protein (either produced as described 15 herein or chemically synthesized) can be used in a vaccine formulation comprising the protein and a compatible pharmaceutical carrier. The protein can be used as purified in such formulations, or it can be made more immunogenic by modifications known in the art. For example, the protein can 20 be converted into a highly immunogenic matrix by reaction with a cross-linking agent such as 1,3-dicyclohexylcarbodiimide. Alternatively, the protein could be covalently coupled to a highly immunogenic protein carrier molecule, either directly or with an appropriate linker molecule. 25 Carrier molecules which could be used include, e.g., limpet hemocyanin and various bacterial toxoids (inactive toxins) such as diphtheria toxoid. Where the gag/env protein is conjugated to a bacterial toxoid, a bivalent vaccine formulation can be produced that will provide protection against 30 both AIDS and the bacterium from which the toxoid was derived.

Routes of administration, antigen dose, number frequency of injections are all factors falling within the ordinary 35 skill in the art.

EXAMPLE

The following is a non-limiting example illustrating the methods by which a recombinant vector encoding the gag/env protein of the HTLV-III virus can be produced. In this example, the following steps were carried out, each of which will be described in detail below:

- 10 (1) The DNA sequence encoding residues 15-512 (all but the first 14 amino-terminal residues) of the gag gene was excised from recombinant phage clone λ HXB-3 and ligated into E. coli expression plasmid pEV-vrf2 to produce plasmid pEV2/gag 15-512;
- 15 (2) DNA sequences corresponding the env amino acid residues 319-331 were deleted from expression plasmid pEV3/env 44-640 by primer-directed mutagenesis to produce plasmid pEV/env 44-640 ϕ 319-331;
- 20 (3) Primer-directed mutagenesis was carried out on plasmid pEV/env 44-640 Δ 319-331 to produce the deletion of nucleotides encoding amino acid residues 514-524 and plasmid pEV3/env 44-640 ϕ 319-331 Δ 514-524; and
- 25 (4) A restriction endonuclease fragment of the env gene from plasmid pEV/env 44-640 Δ 319-331 Δ 514-524 encoding env residues 467-640 Δ 514-524 was
- 30 ligated into cleaved plasmid pEV2/gag 15-512, thereby producing a fusion gene encoding gag residues 15-436 and env residues 467-640 Δ 514-524 in plasmid pEV2/gag 15-436/env 467-640 Δ 514-524.

At each stage of the construction plasmids were reproduced by transformation into E. coli strain MC1061 (pRK248cIts).

5 A. GENERAL PROCEDURES FOR RECOMBINANT VECTOR PREPARATION

DNA PREPARATION

Small scale isolation of plasmid DNA from 1 ml of
10 saturated overnight cultures was carried out according to the procedure of Birnboim et al. [Nucleic Acids Research 7:1513 (1979)]. This procedure allows the isolation of a small quantity of DNA from a bacterial colony for analytical purposes. Larger amounts of plasmid DNA were prepared using
15 1-liter cultures following a standard protocol with cesium chloride centrifugation.

CONDITIONS FOR ENZYMATIC REACTIONS

20 The restriction enzymes and the T4 DNA ligase used were all products of New England BioLabs, Beverly, MA. The methods and conditions for the use of these enzymes were those published by the manufacturer.

25 For the restriction endonucleases, a unit of activity is defined as the amount of enzyme needed to produce a complete digest of 1.0 µg DNA in 60 minutes in a total reaction volume of 0.05 ml, with digestion carried out at 37°C. The digestion mixtures, in addition to the DNA to be cleaved,
30 contained 100 µg/ml bovine serum albumin and the following buffer components:

BglII : 100 mM NaCl, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl₂
and 10 mM 2-mercaptoethanol (2-ME)

35

ClaI : 50 mM NaCl, 6 mM Tris-HCl (pH 7.9) and 6 mM MgCl₂

HincII : 100 mM NaCl, 10 mM Tris-HCl (pH 7.4), 7 mM MgCl₂
and 1 mM dithiothreitol (DTT)

5 HindIII: 50 mM NaCl, 50 mM Tris-HCl (pH 8.0) and 10 mM
MgCl₂

HpaI : 6 mM KCl, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl₂
and 1 mM DTT

10 PstI : 100 mM NaCl, 10 mM Tris-HCl (pH 7.5) and 10 mM
MgCl₂

PvuII : 60 mM NaCl, 6 mM Tris-HCl (pH 7.5), 6 mM MgCl₂
and 6 mM 2-ME

15 StuI : 100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 10 mM MgCl₂
and 6 mM 2-ME

T4 DNA ligation was carried out at 16°C in a mixture
20 containing the DNA and 50 mM Tris-HCl (pH 7.8), 10 mM
MgCl₂, 20 mM DTT, 1.0 mM ATP and 50 µg/ml bovine serum
albumin. A unit of T4 DNA ligase activity is defined as the
amount required to give 50% ligation of HindIII fragments of
lambda DNA in 30 minutes at 16°C in 20 µl of incubation
25 mixture and a 5' DNA termini concentration of 0.12 µM (300
µg/ml).

PURIFICATION OF DNA FRAGMENTS IN AGAROSE

30 Following restriction endonuclease cleavage, DNA
fragments for cloning were isolated by electrophoresis in 1%
agarose. After visualization by 1 µg/ml ethidium bromide,
slices of the gel containing desired DNA fragments were
extruded through a 21 gauge needle into 4 ml of a solution
35 containing 10 mM Tris-HCl (pH 7.4), 1 mM EDTA and 300 mM
NaCl. This mixture was then frozen for 3 hours at -80°C,
thawed for 30 minutes at 37°C and centrifuged at 10,000 x g

for 30 minutes. The supernatant fluid was filtered through a 0.45 micron Millex filter, concentrated to 0.25 ml with sec-butanol and ethanol precipitated three times with 10 µg of E. coli tRNA (transfer RNA) as a carrier.

5

CULTURE MEDIA

M9CA medium contained 10 g Na_2HPO_4 , 3 g KH_2PO_4 , 0.5 g NaCl and 1 g NH_4Cl per liter, with 1 mM MgSO_4 ,
10 0.5% glucose and 0.5% casamino acids, adjusted to pH 7.4.

Luria Broth (LB) contained 5 g Bacto*-yeast extract, 10 g Bacto-tryptone and 10 g NaCl per liter, adjusted to pH 7.5.

15 The antibiotics tetracycline and ampicillin were added to final concentrations of 15 and 50 µg/ml, respectively, where indicated.

TRANSFORMATION AND ISOLATION OF RECOMBINANTS

20

The transformation of E. coli strain MC1061 (pRK248cIts) was carried out using a modification of the protocol of Kushner [in Genetic Engineering, eds. Boyer et al., Elsevier/North-Holland, Amsterdam, p. 17 (1978)],
25 essentially as follows.

Two-hundred ml of the bacterial cells were grown at 30°C in LB to an O.D.₆₀₀ of between 0.5 and 1.0, after which the cells were collected by centrifugation at 6,000 x g for
30 5 minutes at 4°C and resuspended in 50 ml of a solution containing 10 mM morpholinopropane sulfonic acid (MOPS; pH 7.0) and 10 mM RbCl. The cells were again collected by centrifugation and resuspended in 30 ml of a solution containing 10 mM MOPS (pH 6.5), 50 mM CaCl_2 and 10 mM
35 RbCl. After incubation at 0°C for 30 minutes, the cells were collected, resuspended in 6 ml of 10 mM MOPS (pH 6.5) with 50 mM CaCl_2 , 10 mM RbCl and 15% glycerol, aliquoted into
* Registered Trade Mark

40 Eppendorf * tubes (300 μ l/tube) and frozen at -80°C .

Transformation was performed by thawing a 100 μ l aliquot of the cells and incubating for 30, 2 and 2 minutes at 0° , 37° and 0°C , respectively in the presence of a 10 μ l sample of ligation mixture containing about 100 ng of DNA and adding 0.1 to 0.5 ml of LB to the tube. The tube was then incubated at 22°C for 60 minutes, after which 200 μ l of the cell suspension were spread onto an LB plate containing ampicillin and incubated at 30°C for 20 hours.

CELL GROWTH AND INDUCTION OF GENE EXPRESSION

Cultures of E. coli MC1061 containing plasmid pRK248cIts and an expression plasmid were grown in M9CA medium to mid-log phase at 30°C and then transferred to 42°C to inactivate the λ P_L repressor. After a 2 hour incubation at 42°C , cells from 1 ml of the induced culture were collected by centrifugation and resuspended in TG buffer containing 10 mM Tris-HCl (pH 7.4) and 10% glycerol in preparation for analysis.

SDS POLYACRYLAMIDE GEL ELECTROPHORESIS AND WESTERN BLOT ANALYSIS

Induced cells resuspended in Tris-glycine (TG) buffer were mixed with an equal volume of 2x sample buffer [Laemmli, Nature 227:680 (1970)], incubated at 95°C for 5 minutes and subjected to SDS polyacrylamide gel electrophoresis in 12.5% gels as described by Laemmli. Following electrophoresis, the proteins from the gel were electroblotted onto a 0.1 micron nitrocellulose membrane for 6 hours at 95 volts in 12.5 mM Tris and 96 mM glycine with 20% methanol and 0.01% SDS at pH 7.5. Western blot analysis was then carried out as described by Towbin et al. [Proc. Natl. Acad. Sci. U.S.A. 76:4350 (1979)].

* Registered Trade Mark

PRIMER-DIRECTED MUTAGENESIS

Primer-directed site specific mutagenesis was performed according to the methods described by Morinaga et al. [Biotechnology 2:636 (1984)]. Synthetic oligonucleotides used to carry out the mutagenesis procedure were prepared by phosphite methodology [Beaucage et al., Tetrahedron Lett. 22:1859 (1981); Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981)] using an automated synthesizer and purified by polyacrylamide gel electrophoresis by the method of Maxam et al., [Methods in Enzymology 65:499 (1980)].

COLONY HYBRIDIZATIONS

Colony hybridizations were performed by the method of Grunstein et al. [Proc. Natl. Acad. Sci, U.S.A. 72:3961 (1975)]. The same oligonucleotide used for primer-directed site specific mutagenesis was used as a probe for the hybridizations after 5' end labeling with ³²P-(-ATP using polynucleotide kinase as described by Maniatis et al. [Cell 15:687 (1978)].

B. CONSTRUCTION OF PLASMID pEV2/GAG 15-512

As noted above, construction of a final expression plasmid expressing the gag/env fusion protein was initiated by construction of a plasmid (pEV2/gag 15-512) containing nucleotides encoding all but the first 14 amino-terminal residues. Some of the nucleotides encoding the carboxyl-terminal gag residues were then replaced by env sequences to obtain the final fusion product.

To make plasmid pEV2/gag 15-512, the DNA sequence encoding residues 15-512 of the gag protein was obtained from 50 µg of recombinant phage lambda clone λHXB-3 containing the HTLV-III proviral genome by cleavage with 50 units of ClaI and 50 units of HincII for 120 minutes at 37°C

to produce a 1700 bp fragment. This DNA fragment was isolated by preparative agarose gel electrophoresis and resuspended in 0.1x TE buffer [1 mM Tris-HCl (pH 7.4) with 0.1 mM EDTA] to a final concentration of 0.03 pmole/ μ l.

5

To receive the gag DNA fragment, 2 μ g of the E. coli expression plasmid pEV-vrf2 were cleaved with 5 units of ClaI and 5 units of PvuII for 60 minutes at 37 °C, and a 1700 bp fragment containing the λ P_L promoter was isolated by electrophoresis in 1% agarose gel and resuspended after ethanol precipitation to a final concentration of 0.03 pmole/ μ l.

Plasmid pEV-vrf2 used in this construction is a derivative of readily available plasmid pBR322 [ATCC 31344]. The construction of plasmid pEV-vrf2 has been described in detail by Crowl et al. [Gene 38:31 (1985)]. Recombinant phage lambda clone λ HXB-3 used in this construction has been described by Shaw et al. [Science 226:1165 (1984)]. This clone was obtained using standard recombinant DNA techniques from the HTLV-III infected H-9 cell line described above. An HTLV-III infected human cell line designated H9/HTLV-IIIB which is suitable for use in this invention has been deposited with the American Type Culture Collection and assigned accession No. CRL8543. Since Shaw et al. have published the sequence of the HTLV-III genome, a DNA probe can easily be constructed using those data which can be used to isolate the genome from H-9 or from any other line capable of propagating the virus.

30

Three-hundredths (300) pmole of the gag/ClaI-HincII fragment were mixed with 0.03 pmole of the pEV-vrf2/ClaI-PvuII fragment and ligated with 200 units of T4 DNA ligase for 18 hours at 15°C in a final volume of 10 μ l. The ligation product was then transformed into E. coli strain MC1061 (pRK248cIts), and transformants were selected by growth on LB agar plates with ampicillin after incubation

35

at 30°C for 18 hours. The recombinant plasmid DNAs were analyzed for correct restriction fragment size following cleavage with BglII, PstI or HindIII. Isolates positive by DNA size analysis were then evaluated for synthesis of the gag precursor polypeptide by SDS polyacrylamide gel electrophoresis and Western blot analysis.

Cultures harboring plasmid pEV2/gag 15-512 were induced at 40°C, and duplicate samples of the induced cells were prepared for analysis by SDS polyacrylamide gel electrophoresis. After electrophoresis, the gel was bisected, and half of the gel was stained with Coomassie brilliant blue, while the other side of the gel was subjected to electroblotting and Western blot analysis using anti-gag antibodies.

The analysis showed that the induced cells produced proteins which migrated as two major bands in the gels having apparent molecular weights of about 56 and 53 Kd. The size of the complete gag 15-512 protein is about 56 Kd. Both of the major proteins reacted with the anti-gag antibodies. A number of minor lower molecular weight proteins which were reactive with the antibodies were also observed.

C. CONSTRUCTION OF PLASMID pEV3/env 44-640 Δ 319-331

The env sequences present in the final exemplary plasmid of this invention were processed in two stages (described in this section and in Section D, below), each of which involved the deletion of specific short nucleotide sequences by primer-directed site specific mutagenesis. The first of these deletions (described in this section) was required to produce plasmid pEV3/env 44-640 Δ 319-331 Δ 514-524 (Section D).

The expression plasmid pEV3/env 44-640, the construction of which from λHXB-3 and the pEV-vrf plasmids has been described by Cowl et al. [Cell 41:979 (1985)], directs the

synthesis of a 68 Kd HTLV-III env specific protein in E. coli. DNA sequences corresponding to env amino acid residues 319-331 were deleted by primer-directed mutagenesis using an 18-mer synthetic oligonucleotide having the sequence 5' GCA TTT GTT AAC ATT AGT 3'. This oligonucleotide was designed to complement env sequences so as to join nucleotides encoding residue 318 to those encoding residue 332. As a result of bringing these sequences together, a new unique HpaI site was introduced into the plasmid DNA, while 39 bp were deleted. The StuI and HindIII sites in plasmid pEV3/env 44-640 were used to form the "gap" for the heteroduplex molecule.

DNA from isolated colonies which were positive for hybridization to the ³²P-labeled synthetic oligonucleotide during colony screening, were transformed into MC1061 (pRK248cIts) and analyzed for the presence of the new, unique HpaI site.

D. CONSTRUCTION OF PLASMID pEV3/env 44-640 Δ 319-331
Δ 514-524

A second deletion within the env coding sequences was created by primer directed mutagenesis using a synthetic oligonucleotide having the sequence 5' AGA GCA GTG GCA GCA GGA 3'. This oligonucleotide positioned sequences encoding residue 513 of the env protein adjacent to those encoding residue 525, thereby facilitating the deletion of the nucleotides encoding residues 514-524. This deletion was produced in the plasmid using the restriction sites HpaI and HindIII to create a single-stranded gap within the env region.

After re-transformation, DNA from positive isolates identified by the ³²P-labeled oligonucleotide probe was analyzed for the 33 bp deletion by restriction cleavage with HpaI and HindIII followed by electrophoresis in 1% agarose.

This deletion was also confirmed by DNA sequencing following the chemical cleavage method of Maxam and Gilbert [Methods in Enzymology 65:499 (1980)].

5 As previously noted, the Δ 514-524 deletion produces a significant increase in the expression of env.

E. CONSTRUCTION OF PLASMID pEV2/gag 15-436/env 467-640
 Δ 514-524

10

Two μ g of pEV2/gag 15-512 were doubly digested with either 5 units of ClaI and 4 units of BglII to produce about a 1300 bp fragment encoding gag residues 15-436 or with 10 units of PstI and 5 units of ClaI to produce about a 1 Kb
15 fragment containing the λ P_L promoter. Three-tenths μ g of pEV3/env 44-640 Δ 319-331 Δ 514-524 were restricted with 10 units of PstI and 4 units of BglII to produce about a 4 Kb fragment encoding env residues 467-640 Δ 514-524. The various DNA fragments thus produced were separated in 1%
20 agarose and recovered as previously described.

Three-hundredths pmole of each of the isolated DNA fragments were mixed and ligated for 18 hours at 15°C in the presence of 200 units of T4 DNA ligase. The products of the
25 ligation mixture were then transformed into MC1061 (pRK248cIts), and transformants were selected on LB agar plates with ampicillin. Plasmid DNA was prepared from unique colonies and analyzed for correct restriction fragment size following digestion with PvuII.

30

Eleven of 12 isolates were positive by DNA analysis for the expected 3505 and 2882 bp PvuII fragments. Two positive isolates were further evaluated for synthesis of the gag/env fusion protein. These cultures were induced, and cell
35 samples were taken for analysis by SDS polyacrylamide gel electrophoresis, electroblotting and Western blots, with the

results shown in Fig. 3.

Panel 1 in Fig. 3 shows Coomassie blue-stained total cell proteins from cells harboring the recombinant plasmid carrying the gag/env fusion gene (g/e) and from control cells (c). Panels 2 and 3 show the results of duplicate samples subjected to Western blot analysis using rabbit polyclonal antibodies against a synthetic peptide corresponding to env residues 500-511 (panel 2) or using sheep polyclonal antibodies against gag protein p24 which is commercially available [panel 3; see Dowbenko et al., Proc. Natl. Acad. Sci. U.S.A. 82:7748 (1985) for description of p24 protein]. In Fig. 3, the immune complexes in panels 2 and 3 were visualized by a second antibody labeled with horseradish peroxidase, and the mobilities of molecular weight standards (in Kd) are indicated. The positions of the gag/env protein bands in the gels are denoted by arrows.

Many modifications and variations of this invention may be made which are intended to be encompassed by its scope, as will become apparent to those skilled in the art. For example, nucleic acid substitutions could be made in the gene coding for the gag/env protein of the invention (using the sequence data contained herein as a reference) and a somewhat different (but functionally equivalent) fusion protein could be produced therefrom. Such an altered product would still be encompassed by this invention as long as it had at least one antigenic determinant corresponding to the sequences of a gag and env protein of an HTLV-III virus. Similarly, the amino acid sequence of the protein itself could be directly manipulated, with the same result. The specific embodiments described herein are offered by way of example only, and the invention is limited only by the terms of the appended claims.

CLAIMS

1. A protein comprising 50 or more amino acids having an amino acid sequence corresponding to at least one antigenic determinant of a HTLV-III gag protein and of a HTLV-III env protein.

2. The protein according to claim 1 of the amino acid sequence

10 Met Asn Arg Ile Arg Ile His Arg Trp Glu Lys Ile Arg Leu Arg
Pro Gly Gly Lys Lys Lys Tyr Lys Leu Lys His Ile Val Trp Ala
Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu
Thr Ser Glu Gly Cys Arg Gln Ile Leu Gly Gln Leu Gln Pro Ser
15 Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn Thr Val
Ala Thr Leu Tyr Cys Val His Gln Arg Ile Glu Ile Lys Asp Thr
Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Ser Lys
Lys Lys Ala Gln Gln Ala Ala Ala Asp Thr Gly His Ser Ser Gln
Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Ile Gln Gly Gln Met
20 Val His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys
Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe
Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met
Leu Asn Thr Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys
Glu Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg Val His Pro
25 Val His Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg
Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln Ile
Gly Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr
Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr
Ser Pro Thr Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu Pro
30 Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu
Gln Ala Ser Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu Leu
Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala Leu
Gly Pro Ala Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly
Val Gly Gly Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met
35 Ser Gln Val Thr Asn Thr Ala Thr Ile Met Met Gln Arg Gly Asn
Phe Arg Asn Gln Arg Lys Met Val Lys Cys Phe Asn Cys Gly Lys
Glu Gly His Thr Ala Arg Asn Cys Arg Ala Pro Arg Lys Lys Gly



Cys Trp Lys Cys Gly Lys Glu Gly His Gln Met Lys Asp Cys Thr
Glu Arg Gln Ala Asn Phe Leu Gly Lys Ile Phe Arg Pro Gly Gly
Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys
Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys
5 Arg Arg Val Val Gln Arg Glu Lys Arg Ala Val Ala Ala Gly Ser
Thr Met Gly Ala Ala Ser Met Thr Leu Thr Val Gln Ala Arg Gln
Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala
Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile
Lys Gln Leu Gln Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys
10 Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Leu
Cys Thr Thr Ala Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser
Leu Glu Gln Ile Trp Asn His Thr Thr Trp Met Glu Trp Asp Arg
Glu Ile Asn Asn Tyr Thr Ser Phe Asn Ala Val Val Tyr His Ser
15 or a functional equivalent thereof.

3. A protein according to claim 1 or 2 in essentially pure form.

20 4. A DNA sequence coding for a protein as claimed in any one of claims 1 to 3.

5. The DNA sequence according to claim 4 in which the DNA sequence comprises all or part of the nucleic acid
25 sequence

ATGAATAGAA TTCGGATCCA TCGATGGGAA AAAATTCGGT TAAGGCCAGG
GGGAAAGAAA AAATATAAAT TAAACATAT AGTATGGGCA AGCAGGGAGC
TAGAACGATT CGCAGTTAAT CCTGGCCTGT TAGAAACATC AGAAGGCTGT
30 AGACAAATAC TGGGACAGCT ACAACCATCC CTTCAGACAG GATCAGAAGA
ACTTAGATCA TTATATAATA CAGTAGCAAC CCTCTATTGT GTGCATCAAA
GGATAGAGAT AAAAGACACC AAGGAAGCTT TAGACAAGAT AGAGGAAGAG
CAAAACAAAA GTAAGAAAAA AGCACAGCAA GCAGCAGCTG ACACAGGACA
CAGCAGTCAG GTCAGCCAAA ATTACCCTAT AGTGCAGAAC ATCCAGGGGG
35 AAATGGTACA TCAGGCCATA TCACCTAGAA CTTTAAATGC ATGGGTAAAA
GTAGTAGAAG AGAAGGCTTT CAGCCCAGAA GTAATACCCA TGTTTTTCAGC



ATTATCAGAA GGAGCCACCC CACAAGATTT AAACACCATG CTAAACACAG
TGGGGGGACA TCAAGCAGCC ATGCAAATGT TAAAAGAGAC CATCAATGAG
GAAGCTGCAG AATGGGATAG AGTACATCCA GTGCATGCAG GGCCTATTGC
ACCAGGCCAG ATGAGAGAAC CAAGGGGAAG TGACATAGCA GGAECTACTA
5 GTACCCTTCA GGAACAAATA GGATGGATGA CAAATAATCC ACCTATCCCA
GTAGGAGAAA TTTATAAAAG ATGGATAATC CTGGGATTAA ATAAAATAGT
AAGAATGTAT AGCCCTACCA GCATTCTGGA CATAAGACAA GGACCAAAAG
AACCTTTTAG AGACTATGTA GACCGGTTCT ATAAACTCT AAGAGCCGAG
CAAGCTTCAC AGGAGGTAAA AAATTGGATG ACAGAAACCT TGTGGTCCA
10 AAATGCGAAC CCAGATTGTA AGACTATTTT AAAAGCATTG GGACCAGCGG
CTACACTAGA AGAAATGATG ACAGCATGTC AGGGAGTAGG AGGACCCGGC
CATAAGGCAA GAGTTTGGC TGAAGCAATG AGCCAAGTAA CAAATACAGC
TACCATAATG ATGCAGAGAG GCAATTTTAG GAACCAAGA AAGATGGTTA
AGTGTTTCAA TTGTGGCAA GAAGGGCACA CAGCCAGAAA TTGCAGGGCC
15 CCTAGGAAA AGGGCTGTTG GAAATGTGGA AAGGAAGGAC ACCAAATGAA
AGATTGTACT GAGAGACAGG CTAATTTTTT AGGGAAGATC TTCAGACCTG
GAGGAGGAGA TATGAGGGAC AATTGGAGAA GTGAATTATA TAAATATAAA
GTAGTAAAAA TTGAACCATT AGGAGTAGCA CCCACCAAGG CAAAGAGAAG
AGTGGTGCAG AGAGAAAAA GAGCAGTGGC AGCAGGAAGC ACTATGGGCG
20 CAGCGTCAAT GACGCTGACG GTACAGGCCA GACAATTATT GTCTGGTATA
GTGCAGCAGC AGAACAATTT GCTGAGGGCT ATTGAGGCGC AACAGCATCT
GTTGCAACTC ACAGTCTGGG GCATCAAGCA GCTCCAGGCA AGAATCCTGG
CTGTGGAAAG ATACCTAAAG GATCAACAGC TCCTGGGGAT TTGGGGTTGC
TCTGGAAAAC TACTTTGCAC CACTGCTGTG CCTTGGAATG CTAGTTGGAG
25 TAATAAATCT CTGGAACAGA TTTGGAATCA CACGACGTGG ATGGAGTGGG
ACAGAGAAAT TAACAATTAC ACAAGCTTTA ATGCGGTAGT TTATCACAGT
TAA

or a functional equivalent thereof.

30

6. A recombinant vector comprising a DNA sequence according to claim 4 or 5 capable of directing expression of said DNA sequence in a compatible unicellular host organism.

35

7. A recombinant vector according to claim 6 which is plasmid pEV2/gag15-436/env 467-640 Δ 514-524.



8. A unicellular organism containing a recombinant vector as claimed in claim 6 or 7.

5 9. A unicellular organism according to claim 8 which is a procaryotic cell.

10. A unicellular organism according to claim 9 which is an Escherichia coli cell.

10 11. A unicellular organism according to claim 10 which is Escherichia coli MC 1061 cell.

12. A unicellular organism according to claim 8 which is a eucaryotic cell.

15 13. A protein according to any one of claims 1 to 3 as constituent of a vaccine.

20 14. A process for producing a protein as claimed in any one of claims 1 to 3, comprising

25 (a) culturing a unicellular organism containing a recombinant vector as claimed in claim 6 or 7 under appropriate conditions of growth so that said protein is expressed; and

30 (b) isolating said protein from the culture and, if desired, purifying it.

15. A process according to claim 14 wherein the unicellular organism is an E. coli cell.

35



16. A process according to claim 15 wherein the recombinant vector is plasmid pEV2/gag 15-436/env 467-640 Δ 514-524.

5 17. A process for preparing a unicellular organism as claimed in any one of claims 8 to 12, characterized by introduction of a recombinant vector as claimed in claim 6 or 7 into a unicellular organism.

10 18. A process according to claim 17 in which the recombinant vector is introduced into the unicellular organism by transformation.

15 19. A process according to claim 17 in which the recombinant vector is introduced into the unicellular organism by transduction.

20 20. A process according to claim 17 in which the recombinant vector is introduced into the unicellular organism by transfection.

21. A process for detecting the presence of antibodies against AIDS viruses in human serum, comprising:

25 (a) labeling a protein of any one of claims 1-3;

(b) reacting the labeled protein of step (a) with a human serum sample and, allowing labeled protein-antibody complexes to form in the reaction mixture; and

30 (c) determining the labeled protein-antibody complexes of step (b).

22. A process for detecting the presence of antibodies
35 against AIDS viruses in human serum, comprising:



(a) immobilizing a protein of claims 1-3 on a solid support;

(b) contacting a human serum sample with the immobilized protein of step (a) and allowing immobilized protein-antibody complexes to form;

(c) washing away unbound protein and antibodies from the complexes of step (b); and

(d) determining such complexes by the addition of a reagent selected from the group consisting of labeled *Staphylococcus aureus* protein A and a labeled second anti-human IgG antibody.

23. A process for detecting the presence of AIDS viruses or fragments therefrom in human serum or other biological fluid, comprising:

(a) reacting a human serum or other biological fluid sample with a known titer of antibodies raised against a protein as claimed in any one of claims 1 to 3;

(b) allowing the antibodies and sample to interact to form antigen-antibody complexes in the reaction mixture; and

(c) detecting the antigen-antibody complexes of step (b).

24. The process according to claim 23 in which the antibodies are enzyme-labeled, and the antigen-antibody complexes formed in the reaction mixture are detected by enzyme-linked immunosorbent assay.

25. The process according to claim 23 in which a known amount of a protein of claims 1-3 labeled with a radioactive



label is added to the serum or other biological fluid sample, and the antigen-antibody complexes formed in the reaction mixture are detected by radioimmunoassay.

5 26. A process for the preparation of a vaccine comprising mixing a protein of claims 1-3 with a physiologically acceptable carrier.

10 27. A process for the preparation of antibodies against AIDS viruses comprising injecting into a mammalian or avian animal a sufficient amount of a protein of claims 1-3 to elicit the production of antibodies against said protein and recovering said antibodies from the serum of said animals.

15 28. A vaccine formulation comprising a protein of claims 1-3 and a compatible pharmaceutical carrier.

20 29. Antibodies raised against a protein according to claims 1-3.

25 30. The antibodies of claim 29 which are monoclonal antibodies.

30

35

35



31. The use of a protein according to any one of claims 1 to 3 for the preparation of a protective immunization vaccine.

5 32. The use of a protein according to any one of claims 1 to 3 for the preparation of antibodies against AIDS viruses.

10 33. The use of a protein according to any one of claims 1 to 3 for detecting the presence of antibodies against AIDS viruses in human serum.

15

20

25

30

35



* C L M S *

34. A protein as claimed in any one of claims 1 to 3
whenever prepared by a process as claimed in claim 14.

35. A unicellular organism as claimed in any one of
5 claims 8 to 12 whenever prepared by a process as claimed in
any one of claims 17 to 20.

36. Antibodies as claimed in claim 29 or 30 whenever
prepared by a process as claimed in claim 27.

10

37. A vaccine as claimed in claim 28 whenever prepared
by a process as claimed in claim 26.

15

20

25

30

35



38. A test kit for the determination of antibodies against AIDS virus comprising in a container a protein according to any one of claims 1-3.

5 39. A test kit for the determination of AIDS virus comprising in a container antibodies against AIDS virus elicited by a protein according to any one of claims 1-3.

40. A protein, as claimed in claim 1, substantially
10 as hereinbefore described.

41. A DNA sequence as claimed in claim 4, substantially as hereinbefore described.

15 42. A recombinant vector as claimed in claim 6, substantially as hereinbefore described.

43. A unicellular microorganism as claimed in claim 8, substantially as hereinbefore described.
20

44. A process as claimed in any of claims 14, 17, 21, 22, 23, 26 and 27, substantially as hereinbefore described.

45. A vaccine as claimed in claim 28, substantially
25 as hereinbefore described.

46. An antibody preparation as claimed in claim 29, substantially as hereinbefore described.

30

35

